What each side can see
The model sees measured properties and historical outcomes. The team sees mechanism, prior programs, competitive context, and the specific biology of the target. Neither view contains the other, so combining them is not a courtesy — it is the only way to cover the full evidence.
Disagreement is a signal, not a tie to break
When a prediction conflicts with expert reading, the useful move is to ask why. A compound flagged as high risk that experts believe in may share a surface property with past failures while differing in the mechanism that actually mattered. Resolving that question often improves the team's understanding of the compound, regardless of which side turns out to be right.
When judgment should override the score
A model trained mostly on small-molecule oral drugs has little to say about a biologic delivered by injection, because almost nothing in its training history resembles that candidate. Its score there is an extrapolation, not an estimate. A team that knows the candidate sits outside the model's training territory should treat the score as weak evidence and let the experimental data carry the decision.
Treating a prediction as a veto — dropping any compound above a score cutoff without review — converts a useful signal into a rule the model was never validated to support.